| Literature DB >> 34222043 |
Luiz Carlos De Mattos1, Ana Iara Costa Ferreira1, Karina Younan de Oliveira1, Fabiana Nakashima1, Cinara Cássia Brandão1,2.
Abstract
The glycosyltransferases encoded by genes from the human ABO, Lewis, and Secretor histo-blood group systems synthesize part of the carbohydrate antigens in hematopoietic and non-hematopoietic tissues. The combined action of these glycosyltransferases strongly influences cell, tissue, mucosa, and exocrine secretion carbohydrate phenotypes, including those serving as habitat for mutualistic and pathogenic microorganisms. A set of reports investigated associations between Toxoplasma gondii infection and the ABO histo-blood group system, but the results are contradictory. As T. gondii uses the gastrointestinal tract as a route for infection, and in this organ, the expression of ABO, Lewis, and Secretor histo-blood group carbohydrates occurs, it is reasonable to suppose some biological relationship between them. This text reviewed association studies published in recent decades focusing on the potential contribution of the ABO, Lewis, and Secretor histo-blood group carbohydrates and infection by T. gondii.Entities:
Keywords: ABO blood group; Toxoplasma gondii; carbohydrates; histo-blood group systems; lewis phenotype; secretor; secretor phenotype
Year: 2021 PMID: 34222043 PMCID: PMC8251793 DOI: 10.3389/fcimb.2021.671958
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 5.293
ABO, Lewis, and Secretor histo-blood group systems data. Modified from De Mattos (2016).
| Systems | HGNC1 | ISBT2 | Chromosomes | Glycosyltransferase (Abbreviations) | IUBMB3 Code | Immunodominant sugar | Antigens |
|---|---|---|---|---|---|---|---|
| Secretor |
| SE | 19q13.3 | α1,2-Fucosyltransferase (FUTII) | EC 2.4.1.69 | Fuc | H type 1 |
| Lewis |
| LE | 19p13.3 | α1,3/4-Fucosyltransferase (FUTIII) | EC 2.4.1.65 | Fuc, GalNAc, Gal | Lea, Leb, ALeb, BLeb |
| ABO |
| ABO | 9q.34.1 | α1,3-N-Acetylgalactosaminyltransferase (GTA) | EC 2.4.1.40 | GalNAc | A type 1, A type 2 |
| α1,3-N-Galactosyltransferase (GTB) | EC 2.4.1.37 | Gal | B type 1, B type 2 |
1HGNC, Human Genome Nomenclature Committee; 2ISBT, International Society for Blood Transfusion; 3International Union of Biochemistry and Molecular Biology.
The relative level of histo-blood group carbohydrates expressed in tissues and exocrine secretions according to the combination of histo-blood group glycosyltransferases. Modified from Perry et al., 2007.
| Systems | Glycosyltransferases | OP type 1 | H | Lea | Leb | A type 1 | B type 1 | ALeb | BLeb | RBC phenotypes |
|---|---|---|---|---|---|---|---|---|---|---|
| ABO, Lewis, Secretor | FUTII + FUTIII + GTA | (+) | (+) | + | +++ | +++ | 0 | ++++ | 0 | A Le(a-b+) |
| ABO, Lewis, Secretor | FUTII + FUTIII + GTB | (+) | (+) | + | +++ | +++ | ++ | 0 | ++++ | B Le(a-b+) |
| ABO, Lewis, Secretor | FUTII + FUTIII + GTA + GTB | (+) | (+) | + | +++ | +++ | ++ | ++++ | ++++ | AB Le(a-b+) |
| ABO, Lewis, Secretor | FUTII + FUTIII | (+) | (+) | + | +++++ | O Le(a-b+) | ||||
| ABO, Lewis, Secretor | FUTII + GTA | + | ++ | +++++ | A Le(a-b-) | |||||
| ABO, Lewis, Secretor | FUTII + GTB | + | ++ | +++++ | B Le(a-b-) | |||||
| ABO, Lewis, Secretor | FUTII + GTA + GTB | + | ++ | +++++ | +++++ | AB Le(a-b-) | ||||
| ABO, Lewis, Secretor | FUTII | + | +++++ | O Le(a-b-) | ||||||
| ABO, Lewis, Non-Secretor | FUTIII + GTA | + | +++++ | A Le(a+b-) | ||||||
| ABO, Lewis, Non-Secretor | FUTIII + GTB | + | +++++ | B Le(a+b-) | ||||||
| ABO, Lewis, Non-Secretor | FUTIII + GTA + GTB | + | +++++ | AB Le(a+b-) | ||||||
| ABO, Lewis, Non-Secretor | FUTIII | + | +++++ | O Le(a+b-) |
OP, Oligosaccharide precursor; RBC, Red blood cell; (+): Very low expression; +, ++: Low expression; +++, ++++ Moderate expression; +++++: High expression.
Studies of the association between ABO, H, Lewis, and Secretor histo-blood group carbohydrates and infection by Toxoplasma gondii and toxoplasmosis.
| Place/Positive | Source | N | Seropositivity | Methods | HBG systems | Association | Phenotypes | Effects | References | |
|---|---|---|---|---|---|---|---|---|---|---|
| n | % | |||||||||
| Tanzania | Blood donors | 208 | 79 | 38.0 | IHA* | ABO | No | — | — |
|
| Norway | Volunteers | 1,788 | 395 | 22.1 | TcT€ | ABO | Yes | B and AB | Susceptibility |
|
| France | Pregnant (MR) | 4,000 | 3,127 | 78.0 | NR# | ABO | No | — | — |
|
| Russia | Patients | 38 | 15 | 39.5 | NR# | ABO | Yes | A | Susceptibility |
|
| Cuba | Blood donors | 1,036 | 684 | 66.0 | IgG ELISA | ABO | Yes | AB | Susceptibility |
|
| Russia | Blood donors | 323 | NR | NR | NR | ABO | Yes | B and AB | Susceptibility |
|
| Czech Republic | Military | 3,250 | 748 | 23.0 | IgM, IgG ELISA | ABO | Yes | B and AB | Susceptibility |
|
| CFT& | ||||||||||
| Philippines | Urban, suburban residents | 140 | 38 | 27.1 | LAT¥ | ABO | Yes | B | Susceptibility |
|
| Brazil | Pregnant women | 367 | 182 | 49.6 | IHA* | ABO, Secretor | No | — | — |
|
| Egypt | Blood donors | 260 | 155 | 59.6 | IgG ELISA | ABO | Yes | O | Susceptibility |
|
| Brazil | Pregnant women (MR) | 1006 | 645 | 64.1 | IgM, IgG ELISA | ABO | No | — | — |
|
| Taiwan | Blood donors | 1,783 | 166 | 9.3 | IgM, IgG ELISA | ABO | No | — | — |
|
| Czech Republic | Military | 491 | 154 | 31.4 | IgM, IgG ELISA | ABO | No | — | — |
|
| Iraq | Blood donors | 400 | 131 | 32.7 | IgM, IgG ELISA | ABO | Yes | AB | Susceptibility |
|
| 136 | 34.0 | LAT | ||||||||
| Iran | Blood donors | 1,480 | 286 | 19.3 | IgM, IgG ELISA | ABO | No | — | — |
|
| Iran | Blood products | 250 | 59 | 23.6 | IgM, IgG ELISA | ABO | Yes | B, AB | Susceptibility |
|
| Iran | Blood donors | 375 | 94 | 25.0 | IgM, IgG ELISA | ABO | No | — | — |
|
| Iran | Blood donors | 500 | 160 | 32.0 | IgM, IgG ELISA | ABO | Yes | B | Susceptibility |
|
| Côte d’Ivoire | Blood donors | 106 | 68 | 64.1 | IgM, IgG ELISA | ABO | No | — | — |
|
| Iran | Blood donors | 491 | 200 | 40.7 | IgM, IgG ELISA | ABO | No | — | — |
|
| Iran | Blood donors | 285 | 48 | 16.8 | IgM, IgG ELISA | ABO | No | — | — |
|
| Iraq | Miscarriage | 200 | 67 | 33.5 | IgM LAT, ELISA | ABO | No | — | — |
|
| Egypt | Blood donors | 276 | 150 | 54.3 | IgM, IgG ELISA | ABO | No | — | — |
|
| Brazil | Pregnant women | 244 | 158 | 64.7 | IgM, IgG ELISA | ABO, Lewis, Secretor | Yes | Le(a-b+) | Resistance |
|
| Brazil | Blood donors | 1,730 | 835 | 48.3 | IgM, IgG ELISA | ABO | No | — | — | Nakashima et al. (Unpublished data) |
*IHA, Indirect Hemagglutination; €TcT, Toxoplasmin Cutaneous Test; &CFT, Complement Fixation Test; ¥LAT, Latex Agglutination Test; #Non Referred; MD, Data from Medical Records.